Mike
1
- Zepbound will be available in the U.S. by the end of the year at a list price of $1,059.87.
- Lilly’s drug was approved for use by adults with a BMI of at least 30, or a BMI of 27 or more with another weight-related health issue.
- Lilly is launching a commercial savings card program to make Zepbound more affordable for patients.
- Eli Lilly shares have soared 67% in 2023 based on anticipation of the drug’s approval.
- The approval could support up to 10 competing weight-loss products with annual sales reaching $100 billion within a decade.
- Zepbound’s most common side effects include nausea, diarrhea, hair loss, and gastroesophageal reflux disease.